Gilead to present lenacapavir HIV trial data at AIDS 2026
Go back to Gilead to present lenacapavir HIV trial data at AIDS 2026| Gilead Sciences (NASDAQ: GILD) | Delayed: 156.04 -1.15 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $157.19 | 52 Week High | $108.63 | |||
| Open | $156.47 | 52 Week Low | $71.39 | |||
| Day High | $157.65 | P/E | 86.21 | |||
| Day Low | $155.76 | EPS | $1.81 | |||
| Volume | 6,070,932 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 145.27 -1.97 (1.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.24 | 52 Week High | $65.46 | |||
| Open | $145.02 | 52 Week Low | $47.97 | |||
| Day High | $145.44 | P/E | 98.82 | |||
| Day Low | $143.41 | EPS | $1.47 | |||
| Volume | 8,381,045 | |||||



